The phase III IMbrave150 trial evaluating the combination of the PD-L1 inhibitor atezolizumab plus bevacizumab has recently represented an important step forward in the medical management of HCC [1]. According to the results of this study, advanced HCC patients receiving atezolizumab – bevacizumab reported statistically significant and clinically meaningful improvements in terms of overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and complete response rate, compared with sorafenib monotherapy

Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma

Ricci A. D.;Brandi G.
2022

Abstract

The phase III IMbrave150 trial evaluating the combination of the PD-L1 inhibitor atezolizumab plus bevacizumab has recently represented an important step forward in the medical management of HCC [1]. According to the results of this study, advanced HCC patients receiving atezolizumab – bevacizumab reported statistically significant and clinically meaningful improvements in terms of overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and complete response rate, compared with sorafenib monotherapy
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/875618
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact